Study guide
12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
Key Takeaways Explain This Topic AI
Statin-associated muscle symptoms (SAMS) span myalgia (normal CK; >75% driven by the nocebo effect), myositis/myopathy (elevated CK > ULN), and rare rhabdomyolysis (CK >10x ULN, myoglobinuria, renal impairment); management requires a 2-4 week drug holiday and rechallenge with low-dose or hydrophilic statins.
Hydrophilic statins (pravastatin, rosuvastatin) rely on active hepatocyte OATP1B1 uptake and exhibit minimal passive skeletal muscle penetration compared to lipophilic statins (atorvastatin, simvastatin), reducing myalgia risk upon rechallenge.
Ezetimibe inhibits the NPC1L1 transporter in jejunal enterocytes, reducing intestinal cholesterol absorption and adding a 15% to 20% incremental LDL-C reduction with proven MACE reduction in the IMPROVE-IT trial.
PCSK9 monoclonal antibodies (evolocumab, alirocumab) prevent LDL receptor degradation, lowering LDL-C by 50% to 60% and reducing cardiovascular events in the FOURIER and ODYSSEY OUTCOMES trials.
Emerging therapies offer non-muscle-toxic mechanisms: bempedoic acid inhibits ATP-citrate lyase exclusively in hepatocytes (due to lack of activating enzyme ACSVL1 in skeletal muscle), inclisiran utilizes siRNA to silence PCSK9 mRNA bi-annually, and icosapent ethyl (purified EPA) reduces MACE by 25% in hypertriglyceridemia.
Last updated: September 2026
12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
Note
Clinical Competency Core : Maximizing lipid-lowering therapy frequently encounters statin-associated muscle symptoms (SAMS) and the need for non-statin pharmacotherapy to achieve strict secondary prevention goals. Cardiac rehabilitation professionals must distinguish subjective myalgia from true toxic myopathy, execute structured drug re-challenge protocols, and understand the pharmacology and trial evidence of ezetimibe, PCSK9 inhibitors, bempedoic acid, inclisiran, and icosapent ethyl.
While statins remain first-line therapy for secondary prevention, real-world clinical practice reveals two major hurdles: statin intolerance and insufficient LDL-C reduction on statin monotherapy. Approximately 10% of cardiac patients report musculoskeletal side effects that threaten adherence, while patients categorized as very high-risk ASCVD frequently fail to reach the stringent <55 mg/dL threshold without combination therapy. Successfully navigating SAMS and integrating non-statin pharmacotherapies is essential for reducing recurrent atherothrombotic events.
Statin-Associated Muscle Symptoms (SAMS): Phenotypes, Diagnosis & Management
Statin-associated muscle symptoms represent the most frequent reason for statin non-adherence and discontinuation in cardiac rehabilitation. SAMS spans a distinct clinical and biochemical spectrum:
Phenotype Clinical Features Serum Creatine Kinase (CK) Level Clinical Action
Myalgia Bilateral proximal muscle aches, stiffness, tenderness, or weakness (thighs, calves, shoulders); preserved muscle power Normal CK (within laboratory reference range, typically <170–200 U/L) Evaluate secondary causes; execute structured drug holiday (2–4 weeks) and low-dose/hydrophilic rechallenge
Myopathy / Myositis Muscle symptoms accompanied by objective weakness Elevated CK > ULN up to 10× Upper Limit of Normal (ULN) Temporarily hold statin; monitor CK until normal; restart at reduced dose or alternate agent
Rhabdomyolysis Severe, excruciating muscle breakdown, muscle necrosis, brown tea-colored urine (myoglobinuria) Extreme CK elevation: >10× ULN (often >40× ULN), acute renal failure (elevated creatinine), hyperkalemia Medical emergency : Permanently discontinue statin; hospitalize for IV hydration and renal protection
The Nocebo / Drucebo Effect in SAMS
Although observational registries report muscle complaints in 10% to 20% of statin-treated patients, large blinded, placebo-controlled randomized clinical trials (such as the GAUSS-3 and SAMSON trials) reveal that over 75% to 80% of muscle symptoms are driven by the nocebo effect (anticipation of negative side effects). When patients are randomized blindly between statin, placebo, and empty tablets, muscle symptom scores on placebo closely match those on active statins.
Predisposing Risk Factors & Drug Interactions
Clinicians must assess secondary vulnerabilities before declaring a patient statin-intolerant:
Endocrine and Metabolic : Unrecognized hypothyroidism (elevated TSH downregulates hepatic LDLR and impairs skeletal muscle mitochondrial oxidative phosphorylation, dramatically increasing statin myotoxicity risk) and severe vitamin D deficiency (<20 ng/mL).
Patient Characteristics : Advanced age (>75 years), female sex, low body mass index (BMI <18.5 kg/m²), renal insufficiency, and heavy alcohol intake.
CYP3A4 Pharmacokinetic Interactions : Lipophilic statins (atorvastatin, simvastatin, lovastatin) undergo hepatic metabolism via the cytochrome P450 3A4 isozyme. Co-administration of potent CYP3A4 inhibitors—including macrolide antibiotics (clarithromycin, erythromycin), azole antifungals (ketoconazole, itraconazole), non-dihydropyridine CCBs (diltiazem, verapamil), amiodarone, HIV protease inhibitors, and large volumes of grapefruit juice (>1 quart daily)—dramatically elevates systemic statin concentrations.
Gemfibrozil Contraindication : Gemfibrozil competitively inhibits the glucuronidation of statin hydroxy acids and impairs hepatic OATP1B1 uptake, multiplying statin area-under-the-curve (AUC) by several fold. Gemfibrozil is strictly contraindicated with statins ; fenofibrate is the preferred fibrate if triglyceride management requires adjunctive therapy.
Structured SAMS Management Algorithm
Obtain Baseline Laboratory Testing : Draw serum CK, TSH, and renal panel to confirm myalgia vs myopathy and exclude hypothyroidism.
Initiate a Statin Holiday : Discontinue the statin for 2 to 4 weeks . If muscle aches fail to resolve during the drug holiday, the symptoms are unrelated to statin therapy.
Transition from Lipophilic to Hydrophilic Statins : Lipophilic agents (atorvastatin, simvastatin, lovastatin) enter non-hepatic tissues via passive membrane diffusion. In contrast, hydrophilic statins (rosuvastatin and pravastatin) are hepatoselective; their cellular uptake requires the liver-specific Organic Anion Transporting Polypeptide 1B1 (OATP1B1) , dramatically minimizing off-target passive penetration into skeletal myocytes.
Alternate-Day or Non-Daily Dosing : Because rosuvastatin (half-life ≈ 19 \approx 19 ≈ 19 hours) and atorvastatin (half-life ≈ 14 \approx 14 ≈ 14 hours) possess extended half-lives, dosing 2 to 3 times weekly (e.g., rosuvastatin 5 to 10 mg on Monday, Wednesday, Friday) achieves 60% to 75% of daily lipid-lowering efficacy while remaining symptom-free.
Ezetimibe: Mechanism, Efficacy & Evidence
Ezetimibe is the established first-line non-statin agent in secondary prevention.
Mechanism of Action : Ezetimibe selectively targets and binds the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter protein on the brush border membrane of jejunal enterocytes. By blocking the active internalization of dietary and biliary cholesterol without inhibiting the absorption of triglycerides, bile acids, or fat-soluble vitamins, ezetimibe reduces cholesterol transport to the liver. Depleted hepatic cholesterol stores upregulate cell-surface hepatic LDL receptors, accelerating LDL clearance from systemic circulation.
Efficacy : Monotherapy lowers LDL-C by 15% to 18%; added to a statin, it provides an incremental 15% to 20% reduction in LDL-C and a 10% to 15% reduction in ApoB.
The IMPROVE-IT Trial : In 18,144 post-ACS patients, adding ezetimibe 10 mg to simvastatin 40 mg lowered median LDL-C from 69.5 mg/dL to 53.7 mg/dL , yielding a significant reduction in cardiovascular death, MI, and stroke (hazard ratio 0.936, p=0.016). This trial confirmed the clinical principle that lowering LDL-C confers cardiovascular protection regardless of the pharmacological mechanism.
PCSK9 Inhibitors: Monoclonal Antibodies
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is a serine protease secreted by hepatocytes that binds to cell-surface LDL receptors, promoting their lysosomal internalization and destruction rather than their recycling to the membrane.
Mechanism of Action : Evolocumab and Alirocumab are fully human monoclonal antibodies (mAbs) that bind circulating PCSK9 with high affinity, preventing PCSK9-mediated LDLR degradation. Hepatic LDL receptors cycle back to the cell surface up to 150 times, dramatically enhancing plasma clearance of LDL, VLDL remnants, and Lp(a).
Efficacy : Lowers LDL-C by 50% to 60% beyond statin therapy, decreases ApoB by 40% to 50%, and lowers Lipoprotein(a) by 20% to 30% .
Trial Evidence :
FOURIER (Evolocumab) : Enrolled 27,564 stable ASCVD patients on statin therapy. Evolocumab reduced median LDL-C to 30 mg/dL and reduced MACE by 15% (p<0.001) without neurocognitive or muscular toxicities.
ODYSSEY OUTCOMES (Alirocumab) : Enrolled 18,924 post-ACS patients, demonstrating significant MACE reductions and a reduction in all-cause mortality among high-risk patients with baseline LDL-C ≥100 mg/dL.
Dosing : Administered via subcutaneous autoinjector every 2 weeks or monthly.
Novel and Emerging Pharmacotherapies
Bempedoic Acid (Nexletol) :
Mechanism : An oral prodrug that inhibits ATP-citrate lyase (ACL) , an essential cytosolic enzyme acting two steps upstream of HMG-CoA reductase in hepatic cholesterol synthesis. Crucially, bempedoic acid requires conversion to bempedoyl-CoA by the enzyme very long-chain acyl-CoA synthetase-1 (ACSVL1) . Because ACSVL1 is highly expressed in hepatocytes but absent in skeletal muscle , bempedoic acid cannot be activated in myocytes and produces zero statin-like skeletal muscle toxicity .
Efficacy & Trial : Lowers LDL-C by 15% to 25% (or ~38% when co-formulated with ezetimibe). The CLEAR Outcomes trial in 13,970 statin-intolerant patients proved a significant 13% reduction in major adverse cardiovascular events.
Inclisiran (Leqvio) :
Mechanism : A synthetic small interfering RNA (siRNA) conjugated with triantennary N-acetylgalactosamine (GalNAc) carbohydrates that bind specifically to asialoglycoprotein receptors on hepatocytes. Once inside the hepatocyte, inclisiran engages the RNA-induced silencing complex (RISC) to cleave PCSK9 mRNA, preventing PCSK9 protein translation.
Dosing & Efficacy : Administered subcutaneously by a healthcare professional at baseline, 3 months, and then every 6 months . Produces sustained, durable ~50% reductions in LDL-C with guaranteed adherence.
Icosapent Ethyl (Vascepa) :
Mechanism : A highly purified ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA) that excludes docosahexaenoic acid (DHA). Unlike mixed fish oils (where DHA raises LDL-C), icosapent ethyl stabilizes endothelial membranes, reduces lipid peroxidation, and inhibits platelet aggregation without increasing LDL-C.
REDUCE-IT Trial : In 8,179 statin-treated patients with established ASCVD or diabetes plus risk factors with elevated fasting triglycerides (135–499 mg/dL), icosapent ethyl 4 g/day produced a landmark 25% relative risk reduction in MACE (p<0.0001).
Clinical Case Scenario: Statin Intolerance Management & Multi-Pathway Success
Clinical Presentation : A 65-year-old male post-CABG reports debilitating bilateral thigh weakness and pain 3 weeks after starting atorvastatin 40 mg. Creatine kinase is mildly elevated at 280 U/L (reference range 30–170 U/L); serum TSH and creatinine are normal.
Multidisciplinary Management :
Statin Holiday : Atorvastatin is held for 3 weeks; muscle pain completely resolves and CK normalizes to 110 U/L.
Hydrophilic Rechallenge : He is initiated on low-dose rosuvastatin 5 mg every other day . Because rosuvastatin is hydrophilic and excluded from myocytes lacking OATP1B1, he remains asymptomatic.
Therapeutic Combination : Because low-dose alternate-day rosuvastatin only lowers his LDL from 138 to 98 mg/dL (far above the <55 mg/dL target), the team adds oral ezetimibe 10 mg daily (reducing LDL to 78 mg/dL) and bempedoic acid 180 mg daily (providing ACL inhibition without muscle exposure).
Clinical Outcome : His repeat LDL-C drops to 48 mg/dL. He successfully participates in Phase II exercise training without muscle pain, demonstrating that multi-pathway non-statin regimens achieve strict secondary prevention goals in patients with partial statin intolerance.